149 related articles for article (PubMed ID: 25485782)
41. Efficacy and safety of bevacizumab in the treatment of human epidermal growth factor receptor type 2 negative metastatic breast cancer: About a large series in moroccan population.
Majid N; Boutayeb S; Errihani H
Indian J Cancer; 2014; 51(3):272-276. PubMed ID: 25494121
[TBL] [Abstract][Full Text] [Related]
42. Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancer.
Price TJ; Bruhn MA; Lee CK; Hardingham JE; Townsend AR; Mann KP; Simes J; Weickhardt A; Wrin JW; Wilson K; Gebski V; Van Hazel G; Robinson B; Cunningham D; Tebbutt NC
Br J Cancer; 2015 Mar; 112(6):963-70. PubMed ID: 25742472
[TBL] [Abstract][Full Text] [Related]
43. Carboplatin and nonpegylated liposomal doxorubicin in primary advanced or recurrent endometrial cancer: a phase 2 trial conducted by AGO Austria.
Volgger B; Zeimet AG; Reinthaller A; Petru E; Schauer C; Klein M; Sevelda-Schwarzgruber U; Bogner G; Wolfram G; Marth C
Int J Gynecol Cancer; 2015 Feb; 25(2):257-62. PubMed ID: 25611899
[TBL] [Abstract][Full Text] [Related]
44. A dose-escalation study of oxaliplatin/capecitabine/irinotecan (XELOXIRI) and bevacizumab as a first-line therapy for patients with metastatic colorectal cancer.
Sato Y; Ohnuma H; Hirakawa M; Takahashi M; Osuga T; Okagawa Y; Murase K; Takada K; Kawano Y; Iyama S; Hayashi T; Sato T; Miyanishi K; Takimoto R; Kobune M; Okita K; Mizuguchi T; Furuhata T; Hirata K; Kato J
Cancer Chemother Pharmacol; 2015 Mar; 75(3):587-94. PubMed ID: 25577134
[TBL] [Abstract][Full Text] [Related]
45. Pharmacogenetic interaction analysis of VEGFR-2 and IL-8 polymorphisms in advanced breast cancer patients treated with paclitaxel and bevacizumab.
Allegrini G; Coltelli L; Orlandi P; Fontana A; Camerini A; Ferro A; Cazzaniga M; Casadei V; Lucchesi S; Bona E; Di Lieto M; Pazzagli I; Villa F; Amoroso D; Scalese M; Arrighi G; Molinaro S; Fioravanti A; Finale C; Triolo R; Di Desidero T; Donati S; Marcucci L; Goletti O; Del Re M; Salvadori B; Ferrarini I; Danesi R; Falcone A; Bocci G
Pharmacogenomics; 2014 Dec; 15(16):1985-99. PubMed ID: 25521357
[TBL] [Abstract][Full Text] [Related]
46. Phase III study on efficacy of taxanes plus bevacizumab with or without capecitabine as first-line chemotherapy in metastatic breast cancer.
Lück HJ; Lübbe K; Reinisch M; Maass N; Feisel-Schwickardi G; Tomé O; Janni W; Aydogdu M; Neunhöffer T; Ober A; Aktas B; Park-Simon TW; Schumacher C; Höffkes HG; Illmer T; Wagner H; Mehta K; von Minckwitz G; Nekljudova V; Loibl S
Breast Cancer Res Treat; 2015 Jan; 149(1):141-9. PubMed ID: 25519041
[TBL] [Abstract][Full Text] [Related]
47. Single-agent bevacizumab is an effective treatment in recurrent glioblastoma.
Hacibekiroglu I; Kodaz H; Erdogan B; Turkmen E; Ozcelik M; Esenkaya A; Saygi HM; Uzunoglu S; Cicin I
Med Oncol; 2015 Feb; 32(2):460. PubMed ID: 25572814
[TBL] [Abstract][Full Text] [Related]
48. Exploratory Subset Analysis of African Americans From the PointBreak Study: Pemetrexed-Carboplatin-Bevacizumab Followed by Maintenance Pemetrexed-Bevacizumab Versus Paclitaxel-Carboplatin-Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB/IV Nonsquamous Non-Small-Cell Lung Cancer.
Reynolds CH; Patel JD; Garon EB; Olsen MR; Bonomi P; Govindan R; Pennella EJ; Liu J; Guba SC; Li S; Spigel DR; Hermann RC; Socinski MA; Obasaju CK
Clin Lung Cancer; 2015 May; 16(3):200-8. PubMed ID: 25516338
[TBL] [Abstract][Full Text] [Related]
49. Proteinuria with first-line therapy of metastatic renal cell cancer.
Land JD; Chen AH; Atkinson BJ; Cauley DH; Tannir NM
J Oncol Pharm Pract; 2016 Apr; 22(2):235-41. PubMed ID: 25505255
[TBL] [Abstract][Full Text] [Related]
50. A multicenter phase I study of pazopanib in combination with paclitaxel in first-line treatment of patients with advanced solid tumors.
Kendra KL; Plummer R; Salgia R; O'Brien ME; Paul EM; Suttle AB; Compton N; Xu CF; Ottesen LH; Villalona-Calero MA
Mol Cancer Ther; 2015 Feb; 14(2):461-9. PubMed ID: 25504632
[TBL] [Abstract][Full Text] [Related]
51. Short-term Results of Trabeculectomy Using Adjunctive Intracameral Bevacizumab: A Randomized Controlled Trial.
Fakhraie G; Ghadimi H; Eslami Y; Zarei R; Mohammadi M; Vahedian Z; Mafi M; Moghimi S
J Glaucoma; 2016 Mar; 25(3):e182-8. PubMed ID: 25493621
[TBL] [Abstract][Full Text] [Related]
52. Incidence and management of ZIv-aflibercept related toxicities in colorectal cancer.
Saif MW; Relias V; Syrigos K; Gunturu KS
World J Clin Oncol; 2014 Dec; 5(5):1028-35. PubMed ID: 25493238
[TBL] [Abstract][Full Text] [Related]
53. Hepatotoxicity induced by trastuzumab used for breast cancer adjuvant therapy: a case report.
Ishizuna K; Ninomiya J; Ogawa T; Tsuji E
J Med Case Rep; 2014 Dec; 8():417. PubMed ID: 25491149
[TBL] [Abstract][Full Text] [Related]
54. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.
Le DT; Durham JN; Smith KN; Wang H; Bartlett BR; Aulakh LK; Lu S; Kemberling H; Wilt C; Luber BS; Wong F; Azad NS; Rucki AA; Laheru D; Donehower R; Zaheer A; Fisher GA; Crocenzi TS; Lee JJ; Greten TF; Duffy AG; Ciombor KK; Eyring AD; Lam BH; Joe A; Kang SP; Holdhoff M; Danilova L; Cope L; Meyer C; Zhou S; Goldberg RM; Armstrong DK; Bever KM; Fader AN; Taube J; Housseau F; Spetzler D; Xiao N; Pardoll DM; Papadopoulos N; Kinzler KW; Eshleman JR; Vogelstein B; Anders RA; Diaz LA
Science; 2017 Jul; 357(6349):409-413. PubMed ID: 28596308
[TBL] [Abstract][Full Text] [Related]
55. Pazopanib and liposomal doxorubicin in the treatment of patients with relapsed/refractory epithelial ovarian cancer: a phase Ib study of the Sarah Cannon Research Institute.
Hainsworth JD; Firdaus ID; Earwood CB; Chua CC
Cancer Invest; 2015 Mar; 33(3):47-52. PubMed ID: 25615852
[TBL] [Abstract][Full Text] [Related]
56. Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in very platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial.
Mahner S; Meier W; du Bois A; Brown C; Lorusso D; Dell'Anna T; Cretin J; Havsteen H; Bessette P; Zeimet AG; Vergote I; Vasey P; Pujade-Lauraine E; Gladieff L; Ferrero A
Eur J Cancer; 2015 Feb; 51(3):352-8. PubMed ID: 25534295
[TBL] [Abstract][Full Text] [Related]
57. Chemotherapy for Endometrial Cancer in Adjuvant and Advanced Disease Settings.
Bestvina CM; Fleming GF
Oncologist; 2016 Oct; 21(10):1250-1259. PubMed ID: 27412393
[TBL] [Abstract][Full Text] [Related]
58. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial.
Makker V; Rasco D; Vogelzang NJ; Brose MS; Cohn AL; Mier J; Di Simone C; Hyman DM; Stepan DE; Dutcus CE; Schmidt EV; Guo M; Sachdev P; Shumaker R; Aghajanian C; Taylor M
Lancet Oncol; 2019 May; 20(5):711-718. PubMed ID: 30922731
[TBL] [Abstract][Full Text] [Related]
59. Targeting angiogenesis in endometrial cancer - new agents for tailored treatments.
Papa A; Zaccarelli E; Caruso D; Vici P; Benedetti Panici P; Tomao F
Expert Opin Investig Drugs; 2016; 25(1):31-49. PubMed ID: 26560489
[TBL] [Abstract][Full Text] [Related]
60. Efficacy of pazopanib monotherapy in patients who had been heavily pretreated for metastatic soft tissue sarcoma: a retrospective case series.
Yoo KH; Kim HS; Lee SJ; Park SH; Kim SJ; Kim SH; La Choi Y; Shin KH; Cho YJ; Lee J; Rha SY
BMC Cancer; 2015 Mar; 15():154. PubMed ID: 25885855
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]